EVLO News and Press, Evelo Biosciences Inc. From 05/12/22

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence of the First Quarter 2022 Financial Results (Unaudited) section, the dates should be &...

Evelo Biosciences press release (NASDAQ:EVLO): Q1 GAAP EPS of -$0.56 beats by $0.04. As of December 31, 2021, cash and cash equivalents were $39.6 million, as compared to cash and cash equivalents of $68.4 million as of March 31, 2021. For further details see: Evelo Biosciences GAAP EPS...

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2022. “This ...

John Maraganore and Tassos Gianakakos, the former CEOs of, respectively, Alnylam Pharmaceuticals (ALNY) and MyoKardia, are joining Evelo Biosciences (NASDAQ:EVLO) as strategic advisors. Maraganore was Alnylam's founding CEO and just left the company last year, while Gianakakos served as MyoKa...

Gainers: Vallon Pharmaceuticals (VLON) +80%. Blueknight Energy Partners (BKEP) +38%. Moving iMage Technologies (MITQ) +37%. RISE Education Cayman (REDU) +15%. Sky Harbour Group (SKYH) +14%. GWG Holdings (GWGH) +14%. Evelo Biosciences (EVLO) +13%. Chindata Group Holdings (CD) +13%. Shattuck La...

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that John Maraganore, Ph.D., founder and longtime former CEO of Alnylam Pharmaceuticals...

Evelo Biosciences (NASDAQ:EVLO) said it will put the EDP1867 program for eczema on hold after clinical benefit was not seen in a phase 1 trial. The company evaluated EDP1867 in a phase 1b trial which included healthy volunteers and patients with moderate atopic dermatitis (ecze...

–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022– –Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023– –Faster release capsule cohort to be added to on-going Phase 2 trial...

Evelo Biosciences Inc. (NASDAQ:EVLO) traded today at a new 52-week high of $19.77. So far today approximately 9.4 million shares have been exchanged, as compared to an average 30-day volume of 305,000 shares. Evelo Biosciences Inc. (NASDAQ:EVLO) is currently priced 2.7% above its average...

CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today presented a late-breaking oral abstract on ...